Clinical trial

Radium Ra 223 With Enzalutamide Compared to Enzalutamide Alone in Men With Metastatic Castration Refractory Prostate Cancer

NCT02199197

Study summary

ClinicalTrials.gov

Radium Ra 223 With Enzalutamide Compared to Enzalutamide Alone in Men With Metastatic Castration Refractory Prostate Cancer

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention Radium Ra 223 Dichloride Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Enzalutamide Normalized identity: enzalutamide View linked drug · Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2014-06-25

PhasePHASE2

Conditions

Prostate Cancerverified · MONDO: prostate cancer

Interventions

Radium Ra 223 DichlorideDRUG

EnzalutamideDRUG · verified · RxNorm: enzalutamide

Sponsors & collaborators

University of Utahlead sponsor

Mapped research locations

Salt Lake CityUtah, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02199197 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.